Respiratory Medicine
Volume 104, Issue 6 , Page 924, June 2010

Corrigendum to “The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update” [Respiratory Medicine 103 (2009) 1098–1113]

  • Stephen Holgate

      Affiliations

    • Infection, Inflammation and Repair Division, School of Medicine, University of Southampton, D level Centre Block (MP810), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0) 23 8079 6960; fax: +44 (0) 23 8070 1771.
    • ,
  • Roland Buhl

      Affiliations

    • Mainz University Hospital, 55131 Mainz, Germany
    • ,
  • Jean Bousquet

      Affiliations

    • Hôpital Arnaud de Villeneuve, FR-34000 Montpellier, France
    • ,
  • Nicola Smith

      Affiliations

    • Novartis Horsham Research Centre, Horsham, RH12 5AB, UK
    • ,
  • Zoya Panahloo

      Affiliations

    • Novartis Horsham Research Centre, Horsham, RH12 5AB, UK
    • ,
  • Pablo Jimenez

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA

Article Outline

 

The authors regret that incorrect data was published within the ‘Evaluating Clinical Response’ section, para 2 on page 1106. The correct data is printed below.

In responders, annualized rates of clinically significant exacerbations were reduced by 60% (0.73 vs 1.84, P < 0.0001 vs placebo), severe exacerbations by 76% (0.24 vs 1.00, P < 0.0001 vs placebo) and total emergency visits by 76% (0.18 vs 0.77, P < 0.0001 vs placebo) (Novartis, data on file).

PII: S0954-6111(10)00163-0

doi:10.1016/j.rmed.2010.04.008

Refers to article:

  • The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update , 13 April 2009

    Stephen Holgate, Roland Buhl, Jean Bousquet, Nicola Smith, Zoya Panahloo, Pablo Jimenez
    Respiratory Medicine August 2009 (Vol. 103, Issue 8, Pages 1098-1113)

Respiratory Medicine
Volume 104, Issue 6 , Page 924, June 2010

Article Tools